Journal Mobile Options
Table of Contents
Vol. 33, No. 5, 2012
Issue release date: July 2012
Section title: Original Research Article
Free Access
Dement Geriatr Cogn Disord 2012;33:334–340

Are Patients Whose Study Partners Are Spouses More Likely to be Eligible for Alzheimer’s Disease Clinical Trials

Grill J.D.a · Monsell S.b · Karlawish J.c
aMary Easton Center for Alzheimer’s Disease Research, Department of Neurology, UCLA David Geffen School of Medicine, Los Angeles, Calif., bNational Alzheimer’s Coordinating Center, University of Washington, Seattle, Wash., and cPenn Memory Center, Penn Center for Bioethics, Departments of Medicine and Medical Ethics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.


Background/Aims: Alzheimer’s disease (AD) clinical trials enroll two participants: a patient and a study partner. The primary caregiver most often fills the role of study partner and most trial study partners are spousal caregivers. Methods: AD trial inclusion criteria were applied to baseline data from 5,674 probable AD dementia research participants in the National Alzheimer’s Coordinating Center Uniform Data Set. Eligibility was compared among patients with spousal, adult child, and other types of study partners. Results: Patients with spousal study partners were more frequently eligible than patients with adult child study partners. Compared to patients with spousal study partners, patients with adult child study partners were more frequently ineligible because of age, residence in skilled nursing facility, low scores on the Mini-Mental State Examination, highscores on the Hachinski Ischemia Scale, and failure to fulfill a minimum number of weekly visits with the study partner. Conclusions: In this sample, patients with adult child study partners were less likely to qualify for AD clinical trials than were patients with spousal study partners. This may contribute to the lower representation of patients with adult child caregivers in these studies.

© 2012 S. Karger AG, Basel


Author Contacts

Joshua D. Grill, PhD
Mary Easton Center for Alzheimer’s Disease Research
UCLA David Geffen School of Medicine
10911 Weyburn Ave, Ste 200
Los Angeles, CA 90095 (USA)
Tel. +1 310 794 2511, E-Mail


Article Information

Accepted: May 2, 2012
Published online: July 2, 2012
Number of Print Pages : 7


Publication Details

Dementia and Geriatric Cognitive Disorders

Vol. 33, No. 5, Year 2012 (Cover Date: July 2012)

Journal Editor: Chan-Palay V. (Boston, Mass.)
ISSN: 1420-8008 (Print), eISSN: 1421-9824 (Online)

For additional information:

Article / Publication Details

First-Page Preview
Abstract of Original Research Article

Accepted: 5/2/2012
Published online: 7/2/2012
Issue release date: July 2012

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 3

ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)

For additional information:

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.